Novavax identified Coronavirus vaccine candidate; accelerated initiation of first-in-human trial to mid-May
On Apr. 8, 2020, Novavax announced it had identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein…
-
-
Biotechnology | COVID-19 | Diagnostics | FDA
InBios received EUA for its Smart Detect SARS-CoV-2 rRT-PCR Kit for detection of virus causing COVID-19
On Apr. 8, 2020, InBios announced that it had received Emergency Use Authorization (EUA) from the FDA for…
-
Karyopharm to evaluate low dose Selinexor as potential treatment for hospitalized patients with COVID-19
On Apr. 7, 2020, Karyopharm Therapeutics announced plans to initiate a global randomized clinical trial for low dose…
-
Mesa Biotech to ship 10,000 Accula SARS-CoV-2 tests for 30 minute rapid molecular point of care diagnosis
On Apr. 7, 2020, Mesa Biotech announced it was shipping 10,000 of its Accula SARS-CoV-2 molecular rapid point…
-
FDA approved Emory University human clinical trials for Emory COVID-19 antiviral
On Apr. 7, 2020, the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug application by…
-
Luminex received FDA Emergency Use Authorization for ARIES SARS-CoV-2 assay to detect virus responsible for COVID-19 disease
On Apr. 6, 2020, Luminex announced announced that the FDA has issued an Emergency Use Authorization for its…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Non-Profit Research | Therapeutics | Vaccine
Rice University established COVID-19 research fund
On Apr. 6, 2020, Rice University announced it had established a research accelerator fund to support projects –…
-
Seattle area philanthropists responded to COVID-19 care and research needs
On Apr. 6, 2020, the University of Washington Medicine (UW) announced that more than $20 million has been…
-
Alzheimer’s trial screening data links high amyloid levels with early stage disease
On Apr. 6, 2020, the first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study…
-
FDA cleared Mesoblast IND for remestemcel use in COVID-19 ARDS patients
On Apr. 6, 2020, Mesoblast announced it had received clearance from the U.S. Food and Drug Administration (FDA)…
-
GSK and Vir Biotechnology entered collaboration to find coronavirus solutions
On Apr. 6, 2020, GSK and Vir Biotechnology announced a binding agreement to enter into a collaboration to…
-
Mateon achieved milestone in development of OT-101, a phase 3 clinical drug candidate, against COVID-19
On Apr. 6, 2020, Mateon Therapeutics announced that it has delivered the requisite testing results to Golden Mountain…
-
AIM ImmunoTech announced NCI award of $14.54 million to study Ampligen as part of five Roswell Park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers
On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center…
-
3M and White House announced plan to import 166.5 million additional respirators into the U.S. over the next three months
On Apr. 6, 2020, 3M and the White House announced a plan to import 166.5 million respirators over…
-
INOVIO initiated phase 1 clinical trial of its COVID-19 vaccine
On Apr. 6, 2020, Inovio Pharma announced the U.S. Food and Drug Administration (FDA) had accepted the company’s…
-
OraSure Technologies received BARDA contract for Rapid Oral Fluid Pan-SARS-Coronavirus in-home self-test
On Apr. 6, 2020, OraSure Technologies announced it had been awarded a $710,310 contract from the Biomedical Advanced…
-
Minneapolis Heart Institute Foundation engaged in COVID-19 STEMI research study
On Apr. 6, 2020, the Minneapolis Heart Institute Foundation (MHIF) announced it was serving as the international coordinating…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza | Non-Profit Research | Therapeutics
Mesa Biotech to develop molecular point-of-care diagnostic test for novel Coronavirus (COVID-19)
On Apr. 4, 2020, Mesa Biotech announced the addition of the novel coronavirus (SARS-CoV-2) to its active influenza…
-
Mayo Clinic named national site for Convalescent Plasma Expanded Access Program
On Apr. 3, 2020, the FDA announced that the Mayo Clinic Mayo Clinic will be the lead institution…
-
BD, BioGX announced FDA Emergency Use Authorization for new COVID-19 diagnostic for use in U.S.
On Apr. 3, 2020, BD (Becton, Dickinson) and BioGX announced that the U.S. Food and Drug Administration (FDA)…
-
OHSU launched in-house COVID-19 testing lab
On Apr. 3, 2020, Oregon Health & Science University (OHSU) announced that it had established an in-house COVID-19…
-
Mary and Ryan Finley donated $3 million to Legacy Health, OHSU to combat COVID-19
On Apr. 3, 2020, Oregon Health & Science University (OHSU) announced that Mary and Ryan Finley, moved by…
-
Penn Medicine launched trial to evaluate hydroxychloroquine to treat, prevent COVID-19
On Apr. 6, 2020, a trial led by the Perelman School of Medicine at the University of Pennsylvania…
-
Biotechnology | Diagnostics | Disease | Genomics | Neurology | NIH | Therapeutics
Single mutation leads to big effects in autism-related gene
On Apr. 2, 2020, a study in Neuron offers clues to why autism spectrum disorder (ASD) is more…
-
The FDA announced publication of ARGOS SARS-CoV-2 reference grade sequence data
On Apr. 2, 2020, the FDAﾗin collaboration with the CDC, the Biodefense and Emerging Infections Research Resources Repository…
-
Novartis announced plan to initiate clinical study of Jakavi in severe COVID-19 patients and establish international compassionate use program
On Apr. 2, 2020, Novartis announced plans to initiate a phase III clinical trial in collaboration with Incyte…
-
Map revealed hidden U.S. hotspots of Coronavirus infection at the country level
On Apr. 2, 2020, a University of Chicago team announced that it had mapped confirmed COVID-19 infections per…
-
Trial drug significantly blocked early stages of COVID-19 in engineered human tissues
On Apr. 2, 2020, an international team led by University of British Columbia (UBC) researcher Dr. Josef Penninger…
-
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors of COVID-19
On Apr. 2, 2020, Vir Biotech and Alnylam Pharma announced an expansion to their broad multi-target existing collaboration…
-
Cerus announced inclusion of pathogen reduction technology in ISBT recommendations for preparation of COVID-19 convalescent plasma
On Apr. 2, 2020, Cerus announced that the International Society of Blood Transfusion (ISBT) Working Party on Global…
